SUDA Pharmaceuticals Ltd (SUDA), based in Australia and the US, is a world leader in reformulating and delivering medication through the oral mucosa.

Patients typically take medication as pills, tablets or capsules yet less than 25% of the medication is absorbed into the bloodstream.

SUDA can increase the bioavailability of administered medications, which means it increases the amount of the drug absorbed by the body so is able to increase the effect of that drug.

SUDA has increased bioavailability up to 95%. This is a major step forward in the evolution of drug delivery technology.

Media Releases

  • Mar 2020   09:44 AM
    SUDA Pharmaceuticals Ltd (ASX: SUD), a leader inoro-mucosal drug delivery, today announces that it has entered into an exclusive licenseagreement with Mitsubishi Tanabe Pharma Korea Ltd (MTPK), a more
  • Feb 2020   06:01 PM
      Key achievements: 1. SUDA secured three new agreements: Cann Pharma Australia for a novel oral spray of cannabinoid derivatives; and two feasibility studies with Laboratorios Ordesa, S.L. more
  • Jan 2020   12:29 PM
    SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, today released its Appendix 4C for the consolidated Group for the second quarter of FY 2020. During the quarter, the more
  • Dec 2019   10:56 AM
    PERTH, AUSTRALIA – 9 December 2019: SUDA Pharmaceuticals Ltd (ASX:SUD), a leader in oromucosal drug delivery, is pleased to announce that it has entered into a feasibility agreement with more
  • Dec 2019   08:25 AM
    SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that it has entered into a fully-funded, feasibility study and option agreement with Laboratorios Ordesa, more
  • Nov 2019   11:13 AM
    Michael Baker joins SUDA Pharmaceuticals from the leading Australian life science fund, Bioscience Managers, where he was based from 2017. As an Investment Manager, he was responsible for deal more
  • Nov 2019   11:11 AM
    SUDA Pharmaceuticals (ASX:SUD), a leader in oro-mucosal drug delivery, is pleased to advise that it has received a refund of $927,970 from the Australian Taxation Office under the R&D Tax more
  • SUDA Results of AGM  (ASX:SUD)
    Nov 2019   11:09 AM
    Details of resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary. All discretionary votes were in favour of the chair and were voted in favour more
  • SUDA AGM Presentation  (ASX:SUD)
    Nov 2019   11:05 AM
    Observations from the Chair  The technology is sound Solid barriers to entry as evidenced by our partners’ willingness to engage Shareholder sentiment at an all more
  • Nov 2019   11:03 AM
    The US based business development role, headed by Andrew Curtis, will cease in 30 days time. This function will be assumed by the incoming CEO and the Company’s international business more

Latest Company News


Contact Information